Datamonitor Healthcare Oncology Disease Analysis: Multiple Myeloma

May 07, 2021

Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage. Plasma cells normally produce antibodies in response to infection or allergens, but in MM a plasma cell clone starts to proliferate and produce excessive amounts of one type of abnormal antibody, referred to as M-protein or paraprotein. In addition to high levels of M-protein, most patients with active MM have some form of organ damage caused by the proliferation of plasma cells and the high levels of protein in the blood and urine. Typical signs of organ damage include hypercalcemia, renal insufficiency, anemia, and bone lesions.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered:

Multiple Myeloma (MM)